These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 11003358

  • 1. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
    Thistlethwaite JR, Nashan B, Hall M, Chodoff L, Lin TH.
    Transplantation; 2000 Sep 15; 70(5):784-90. PubMed ID: 11003358
    [Abstract] [Full Text] [Related]

  • 2. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD, Rajagopalan PR, Hall M.
    Transplantation; 1999 Jan 27; 67(2):276-84. PubMed ID: 10075594
    [Abstract] [Full Text] [Related]

  • 3. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP.
    Lancet; 1997 Oct 25; 350(9086):1193-8. PubMed ID: 9652559
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.
    Keown P, Balshaw R, Khorasheh S, Chong M, Marra C, Kalo Z, Korn A.
    BioDrugs; 2003 Oct 25; 17(4):271-9. PubMed ID: 12899644
    [Abstract] [Full Text] [Related]

  • 5. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, Kahn D, Kashi H, Salmela K, Fricke L, Heemann U, Garcia-Martinez J, Lechler R, Prestele H, Girault D, Simulect Phase IV Study Group.
    Transplantation; 2001 Oct 15; 72(7):1261-7. PubMed ID: 11602853
    [Abstract] [Full Text] [Related]

  • 7. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM, Keating GM.
    Drugs; 2003 Oct 15; 63(24):2803-35. PubMed ID: 14664658
    [Abstract] [Full Text] [Related]

  • 8. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
    Tan J, Yang S, Wu W.
    Transplant Proc; 2005 Mar 15; 37(2):903-5. PubMed ID: 15848570
    [Abstract] [Full Text] [Related]

  • 9. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D, Simulect International Study Group.
    Transplantation; 2003 Jan 15; 75(1):37-43. PubMed ID: 12544868
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
    Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, Chodoff L, Korn A, Hall M.
    Transplantation; 2002 Oct 15; 74(7):961-6. PubMed ID: 12394837
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB.
    Transplantation; 2008 Nov 15; 86(9):1241-8. PubMed ID: 19005406
    [Abstract] [Full Text] [Related]

  • 12. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.
    Lorber MI, Fastenau J, Wilson D, DiCesare J, Hall ML.
    Clin Transplant; 2000 Oct 15; 14(5):479-85. PubMed ID: 11048993
    [Abstract] [Full Text] [Related]

  • 13. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 15; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 14. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Jul 15; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 15. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 16. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
    Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B, CHIC 304 International Liver Study Group.
    Liver Transpl; 2002 Feb 27; 8(2):132-42. PubMed ID: 11862589
    [Abstract] [Full Text] [Related]

  • 17. Use of simulect can reduce the incidence of acute rejection and demonstrates with superior 3-year patient and graft survival rates in renal transplantation.
    Chu SH, Chiang YJ, Huang CC, Lee PH, Hu RH, Lai MK, Chueh SC, Tsai MK.
    Transplant Proc; 2004 Sep 27; 36(7):2108-9. PubMed ID: 15518763
    [Abstract] [Full Text] [Related]

  • 18. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A.
    Transplant Proc; 2007 Dec 27; 39(10):3093-7. PubMed ID: 18089329
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
    Parrott NR, Hammad AQ, Watson CJ, Lodge JP, Andrews CD.
    Transplantation; 2005 Feb 15; 79(3):344-8. PubMed ID: 15699766
    [Abstract] [Full Text] [Related]

  • 20. Basiliximab: a review of its use as induction therapy in renal transplantation.
    McKeage K, McCormack PL.
    BioDrugs; 2010 Feb 01; 24(1):55-76. PubMed ID: 20055533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.